HIV R4P no date logo



Poster Presentations

Posters will be displayed in Hall 2, Level 0 of the Convention Center.

Two poster sessions will be held on Wednesday, 29 October and Thursday, 30 October. The morning poster session will be held from 10:00 – 11:00. Afternoon posters sessions will be accompanied by a reception and will be held from 17:00 – 18:30. Each poster presenter will be available for discussion of their poster during both sessions of their designated presentation day. 

Poster Discussions

These sessions aim to foster and encourage public discussion and debate of important scientific and clinical questions relevant to HIV prevention research. Poster discussion presenters will also present a printed poster.

Oral Poster Discussion Sessions are scheduled on Wednesday, 29 and Thursday, 30 October from 17:15 – 18:05.

Poster discussions have 5 minutes for the oral presentation, accompanied by a maximum of three power point slides, followed by 5 minutes of discussion. 

Wednesday, 29 October
Oral Poster Discussion Sessions include:
• PD01: Community Engagement and Advocacy (Room A)
• PD02: Correlates of Protection in Highly Exposed Seronegative People (Room B)
• PD03: Preclinical and Clinical Vaccine Trials (Room C)

Thursday, 30 October
Oral Poster Discussion Sessions include:
• PD04: Behavioral and Social Sciences (Room A)
• PD05: Glycans and Antibody Effector Functions (Room B)
• PD06: Policy, Advocacy and Modeling (Room C)

Oral Poster discussions will present their printed posters on the same day as their oral presentation.

Poster Themes Presented Wednesday, 29 October

  • P01: Acute Seroconversion
  • P02: Community Engagement and Advocacy
  • P03: Correlates of Protection and Exposure
  • P04 : Correlates of Protection in Highly Exposed Seronegative People
  • P05: Family Planning
  • P06: Financial Incentives
  • P07: Good Participatory Practices and Community Involvement
  • P08: HIV Care
  • P09: HIV Testing and Counseling
  • P10: Immunogens
  • P11: Informed Consent
  • P12: Innate Immunity
  • P13: Key Populations
  • P14: MPT Development
  • P15: Novel Formulations, Agents and Microbicides
  • P16: Passive Antibody Functions
  • P17: Post-exposure Prophylaxis
  • P18: Preclinical Evaluation of Vaginal Films and Gels
  • P19: PrEP Implementation
  • P20: PrEP: Resistance, Modeling and Acceptability
  • P21: Product Acceptability and Adherence
  • P22: Resistance and Treatment Failure
  • P23: Retention and Adherence in Trials
  • P24: T-Cell (CD4 & CD8) Responses
  • P25: Transmission and Viral Diversity
  • P26: Vaccine Clinical 

Poster Themes Presented Thursday, 30 October

  • P27: Adjuvants
  • P28: Behavioral and Social Sciences
  • P29: Circumcision and acceptability
  • P30: Condoms: Attitudes, Use and How to Increase
  • P31: Drug Transporters
  • P32: Ethics and the Law
  • P33: Evaluation of Novel Compounds in Cell- Based Systems
  • P34: Glycans and Antibody Effector Functions
  • P35: HIV Drug Resistance in vitro
  • P36: HIV Incidence and Prevalence
  • P37: Immunogenetics
  • P38: Innovations in Vaccine and Microbicides Studies in Lab and Monitoring
  • P39: Molecular Epidemiology
  • P40: Mucosal Immune Activation and Inflammation
  • P41: Novel Vaccine and Prevention Concepts
  • P42: Participation in Trials: Willingness, Benefits and Challenges
  • P43: Policy, Advocacy and Modeling
  • P44: Preclinical Evaluation of Biomedical Agents in Animal Models Tissues Explants
  • P45: Pregnancy and PMTCT
  • P46: PrEP Trials: Preparing for Demos, Participant Experiences
  • P47: Resource Tracking and Economics
  • P48: Risk Perception
  • P49: Sexually Transmitted Infections
  • P50: Tenofovir Gel: Acceptability and Adherence
  • P51: Therapeutic Vaccine and Viral Latency
  • P52: Treatment as Prevention: Initiation, Adherence, and Monitoring on ARV
  • P53: Vaginal Rings: Baseline Characteristics, Impact on Condoms and Flora